Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.

Abstract

The distinction between myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) often relies on an arbitrary marrow blast cutoff of 30% in pediatrics and 20% in adults. There is little data about the treatment of children with extramedullary myeloid malignancy that has features of both, MDS and AML. Herein, we report for the first time 2 patients MDS/AML (1 with Shwachman-Diamond syndrome and 1 with idiopathic MDS and monosomy 7) who presented with extramedullary complications, received treatment with azacitidine, achieved complete remission and subsequently underwent hematopoietic stem cell transplantation.

• Authors: Iren Shabanova, Michaela Cada, Donna L Johnston, Lesleigh S Abbott, Elaine W Leung, Tal Schechter, Yigal Dror, Robert J Klaassen
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 42 Issue 3 Pg. 170-174 (04 2020) ISSN: 1536-3678 [Electronic] United States
• PMID: 32134844 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antimetabolites, Antineoplastic
• Azacitidine

Topics

• Adolescent
• Antimetabolites, Antineoplastic (therapeutic use)
• Azacitidine (therapeutic use)
• Child, Preschool
• Chromosome Deletion
• Chromosomes, Human, Pair 7
• Humans
• Leukemia, Myeloid, Acute (drug therapy, genetics)
• Male
• Myelodysplastic Syndromes (drug therapy, genetics)
• Shwachman-Diamond Syndrome (complications)